Proctitis

Summary

Proctitis (MONDO:0005538) is a disease and 6 clinical trials. Top therapeutic interventions include budesonide and mesalamine. A subtype of anus disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	proctitis
Mondo ID	MONDO:0005538
EFO	EFO:0005628
MeSH	D011349
DOID	DOID:3127
NCIT	C38011
SNOMED CT	3951002
UMLS	C0033246
MedGen	46113
Is cancer (heuristic)	no

Also known as: anus inflammation · inflammation of anus · rectitis

Disease family

This is a subtype of anus disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › large intestine disorder › rectal disorder › anus disorder › proctitis

Related subtypes (6): imperforate anus, anorectal stricture, anal spasm, anus neoplasm, levator syndrome, anal polyp

Subtypes (2): radiation proctitis, proctocolitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Mesalamine	Approved (phase 4)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Budesonide, Thalidomide.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	4
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01008410	PHASE3	COMPLETED	Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
NCT01008423	PHASE3	COMPLETED	Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
NCT01172444	PHASE3	TERMINATED	Clinical Trial With Mesalamine 1g Suppositories
NCT01349673	PHASE3	TERMINATED	The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis
NCT01837615	PHASE2	COMPLETED	Assessment of Photopill Capsule Treatment for Safety and Feasibility in Ulcerative Proctitis
NCT01966783	PHASE2	COMPLETED	Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BUDESONIDE	4	3
MESALAMINE	4	2